Skip to main content
OpenTrials
Completed

NCT Number: NCT05207189

Biological Sling Allograft (UVT) for the Treatment of Urinary Incontinence in Women Presenting With Synthetic Sling Complications

The purpose of this open, multi center trial is to evaluate a new biological replacement for synthetic slings in the treatment of female stress urinary incontinence.

Completed

Looking for future studies?

Notify Me

Key information

About this study

It was estimated that more than 9 million French people are affected by urinary incontinence, of which 1% are treated surgically. Indeed, if medical treatment or rehabilitation fails, surgical treatment must be considered. Sling implantation is a commonly used surgical technique to treat stress urinary incontinence as it allows for a reduction in surgery time and morbidity and can be placed under local anesthesia. However, the risk of complications associated with the use of synthetic products is high and contributes to the recent decline of popularity of synthetic slings. As the demand for incontinence treatment remains high, fascia autograft surgeries are being proposed, even though they require an additional surgical procedure and expose the patient to complications at the donor site of the graft.

The study product aims to address the growing need for a safer but equally effective implant to avoid autografting while keeping the standard surgical technique.

The aim of this exploratory study is to evaluate a biological sling replacement to failed synthetic slings in the treatment of female stress urinary incontinence.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women over 40 years of age and under 75 years of age.
  • Failure of primary surgical technique with synthetic sling requiring its removal due to complications such as vaginal exposure or urinal tract erosion.
  • Inclusion more than 3 months after primary surgery.
  • Any fistula or abnormality of the urinary tract, any erosion or complication due to the synthetic sling placement must be repaired during surgery. In case of persistence of complication or limited possibility to insert the UVT due to major vesical or urethral lesion, the patient will not be included.
  • Patients with controlled urinal tract infections.
  • Patients who received the study information and provided consent.
  • Patients who are members or the beneficiary of a national health insurance plan.

Exclusion criteria

  • Breast feeding women or women without effective contraception. In absence of effective contraception, a pregnancy test followed by an effective contraception are mandatories for non-menopausal women.
  • Patients with mild cases treated by physiotherapy and pelvic floor exercises for urinary incontinence or without surgical complications.
  • Patients with current urinary infection, severe anemia or other pathologies that counter-indicate surgery.
  • Cystocele and rectocele not treated during the surgery.
  • Persons under guardianship or confined by a judicial or administrative decision.
  • Patients unable to have discernment for rehabilitation, unable to perform follow-up or unable to provide their consent.

Treatment and study plan

UVT

Biological

Chemically-treated, viro-inactivated, freeze-dried and irradiated umbilical vein allograft placed in replacement of a failed synthetic sling during a surgical act performed by the investigator.

Primary outcomes

  1. No major signs of incontinence

    Time frame: 6 months

    Use of less than 2 pads a day

  2. No complication related to investigational product

    Time frame: 6 months

    Evaluation of urinary retention, dysuria, local inflammation, irritation of suture and suspension areas, and other indirect symptoms

Secondary outcomes

  1. Decrease of the signs of complications of the first surgery

    Time frame: 15 days, 6 weeks, 3 months, 6 months, 12 months

    Monitoring of urinary retention, dysuria, local inflammation, irritation of suture and suspension areas, and other indirect symptoms

  2. Decrease of pain and analgesic consumption

    Time frame: 15 days, 6 weeks, 3 months, 6 months, 12 months

    Pain evaluated from 0: no pain to 10: worst imaginable pain on visual analog scale (VAS)

  3. Progressive recuperation of continence

    Time frame: 15 days, 6 weeks, 3 months, 6 months, 12 months

    Continence evaluated by uroflow test and 3-day voiding diary

  4. Decrease of Urinary Incontinence (UI) severity

    Time frame: 6 weeks, 3 months, 6 months, 12 months

    Decrease in the score of the International Consultation on Incontinence Questionnaire - Urinary Incontinence - Short Form (ICIQ-UI-SF) (0 = no UI, 21 = very severe UI)

  5. Decrease of distress caused by UI symptoms

    Time frame: 6 weeks, 3 months, 6 months, 12 months

    Decrease of the Urogenital Distress Inventory (UDI-6) score (0 = no distress caused by UI symptoms, 100 = highest possible distress cause by UI symptoms)

  6. Improvement of health-related quality of life

    Time frame: 6 weeks, 3 months, 6 months, 12 months

    Decrease of the Incontinence Impact Questionnaire (IIQ-7) score (0 = no impact of UI on health-related quality of life, 100 = highest possible impact of UI on health-related quality of life)

Sponsors and collaborators

Lead sponsor

TBF Genie Tissulaire

Industry

Registry information

Official study title

Phase II Study Evaluating the Treatment of Women Urinary Incontinence by Suburethral Slings; UVT Allograft; in Patients Presenting With Complication of the Synthetic Sling Treatment

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
Jan 26, 2022
Registry last updated
Jun 5, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.